Evaluation of the abuse potential of pitolisant a selective H3-receptor antagonist/inverse agonist for the treatment of adult patients with narcolepsy with or without cataplexy

摘要

To evaluate the human abuse potential of pitolisant, a selective histamine 3 (H )-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.